CN120239610A - 用于治疗痉挛的ngf - Google Patents

用于治疗痉挛的ngf Download PDF

Info

Publication number
CN120239610A
CN120239610A CN202380067388.4A CN202380067388A CN120239610A CN 120239610 A CN120239610 A CN 120239610A CN 202380067388 A CN202380067388 A CN 202380067388A CN 120239610 A CN120239610 A CN 120239610A
Authority
CN
China
Prior art keywords
ngf
mutant protein
seq
tbi
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380067388.4A
Other languages
English (en)
Chinese (zh)
Inventor
马尔塞洛·阿莱格雷蒂
安德烈亚·阿拉米尼
劳拉·布兰多利尼
弗兰卡·卡塔尼
弗拉维奥·曼泰利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dompe Farmaceutici SpA
Original Assignee
Dompe Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farmaceutici SpA filed Critical Dompe Farmaceutici SpA
Publication of CN120239610A publication Critical patent/CN120239610A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN202380067388.4A 2022-09-23 2023-09-25 用于治疗痉挛的ngf Pending CN120239610A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22197562.6 2022-09-23
EP22197562.6A EP4342485A1 (en) 2022-09-23 2022-09-23 Ngf for the treatment of spasticity
PCT/EP2023/076387 WO2024062135A1 (en) 2022-09-23 2023-09-25 Ngf for the treatment of spasticity

Publications (1)

Publication Number Publication Date
CN120239610A true CN120239610A (zh) 2025-07-01

Family

ID=83438536

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380067388.4A Pending CN120239610A (zh) 2022-09-23 2023-09-25 用于治疗痉挛的ngf

Country Status (7)

Country Link
EP (2) EP4342485A1 (https=)
JP (1) JP2025532676A (https=)
CN (1) CN120239610A (https=)
AU (1) AU2023345675A1 (https=)
CA (1) CA3266315A1 (https=)
IL (1) IL319010A (https=)
WO (1) WO2024062135A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026022244A1 (en) 2024-07-23 2026-01-29 Chiesi Farmaceutici S.P.A. A polypeptide for use in the therapeutic management of acute ischaemic stroke

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2213861T3 (es) 1998-10-09 2004-09-01 Scil Proteins Gmbh Procedimiento de obtencion de ngf-beta activa.
CN1112215C (zh) * 1999-12-28 2003-06-25 潘晓东 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途
CN104203264B (zh) 2011-12-19 2018-08-28 瓦克化学有限公司 新型proNGF突变体及其在生产β-NGF中的用途
WO2017157325A1 (zh) * 2016-03-18 2017-09-21 舒泰神（北京）生物制药股份有限公司 神经生长因子融合蛋白、制备方法及其用途
IT201600112420A1 (it) * 2016-11-08 2018-05-08 Univ Cattolica Del Sacro Cuore Nuova formulazione per via intranasale
MA52351A (fr) 2018-04-27 2021-05-26 Chiesi Farm Spa Production du facteur de croissance nerveuse (ngf) et de mutéines de celui-ci
HRP20241431T1 (hr) * 2019-09-17 2024-12-20 Chiesi Farmaceutici S.P.A. Mutant ngf za upotrebu u liječenju ili prevenciji oftalmoloških poremećaja
CN114829384B (zh) * 2020-11-19 2023-12-12 舒泰神（北京）生物制药股份有限公司 长效神经生长因子多肽及其用途

Also Published As

Publication number Publication date
WO2024062135A1 (en) 2024-03-28
CA3266315A1 (en) 2024-03-28
EP4342485A1 (en) 2024-03-27
IL319010A (en) 2025-04-01
AU2023345675A1 (en) 2025-03-06
EP4590324A1 (en) 2025-07-30
JP2025532676A (ja) 2025-10-01

Similar Documents

Publication Publication Date Title
Kostich et al. Inhibition of AAK1 kinase as a novel therapeutic approach to treat neuropathic pain
JP2838073B2 (ja) 痛覚脱失を生じるためならびにニューロパシー性疼痛疾患の進行を阻害するための組成物および処方物
AU2006227528B2 (en) Use of ADNF polypeptides for treating peripheral neurotoxicity
CN101288768A (zh) 用于治疗渐进神经退化症的医药组合物
EP2679239A1 (de) Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
AT510585B1 (de) Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
RU2715908C2 (ru) Применение нейрегулина для лечения повреждения периферических нервов
US20240226238A1 (en) Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction
Leung et al. Cholinergic modulation of general anesthesia
CN120239610A (zh) 用于治疗痉挛的ngf
US7468353B2 (en) Biologically active substance of a vasoactive intestinal peptide for treating interstitial lung diseases
TWI902336B (zh) 二價金屬乳酸鹽在製備修復神經損傷之製品中的用途
Baca-Alonso et al. Neurotrophic effects of GH and GnRH in a full sciatic nerve transection model in male rats
US20210379152A1 (en) Methods and compositions for treating pain
CN115087457A (zh) 用于治疗Tau蛋白病的肽组合物和方法
JP2001519356A (ja) 免疫起源の神経学上の疾患を処置するための、ニューロン及びリンパ球カリウムチャンネル阻害剤の使用
WO2000013705A1 (en) Use of tgf-beta inhibitors for treating cerebral disorders
JP2009504636A (ja) 血漿または血清を含む神経損傷治療用の医薬組成物
CN116802208A (zh) 帕金森氏病的治疗
RU2575570C2 (ru) Применение нейрегулина для лечения повреждения периферических нервов
JP2665766B2 (ja) 記憶力増強剤
Takenami et al. Comparison of neurotoxicity of intrathecally administered fentanyl and bupivacaine in rats
Hilt et al. Early Experiences with Trophic Factors as Drugs for Neurological Disease: Brain-Derived Neurotrophic Factor and Ciliary Neurotrophic Factor for ALS
Amano Study in the Chiropractic Manipulation Facilitating Regeneration of the Sciatic Nerve in Rats
Nevšímalová et al. P463 Sleep disturbances in advanced stages of neurometabolic disorders of CNS in children and melatonin profile changes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination